Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,207 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study Powder Clear all
Completed Phase 3 Interventional Results available

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02164513
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone furoate (FF), vilanterol (VI), umeclidinium bromide (UMEC)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
10,355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
269
States / cities
Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 226 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients

NCT01746095
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Vancomycin hydrochloride inhalation powder, Placebo inhalation powder
Drug
Lead sponsor
Savara Inc.
Industry
Eligibility
12 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
38
States / cities
Mobile, Alabama • Little Rock, Arkansas • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 30, 2026, 10:57 AM EDT
Terminated Phase 4 Interventional Results available

Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)

NCT03219866
View directory record Official record
Conditions
COPD, COPD Exacerbation
Interventions
Nebulizers, Dry Powder Inhaler, Brovana, Pulmicort, Atrovent, Advair Diskus, Spiriva HandiHaler
Device · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 30, 2026, 10:57 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

NCT06968845
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
LTI-03, Dry Powder Inhaler, Placebo
Drug · Device
Lead sponsor
Rein Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 10:57 AM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.

NCT03217838
View directory record Official record
Conditions
Acute Myeloid Leukaemia
Interventions
AZD2811, Azacitidine, Venetoclax
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
10
States / cities
Denver, Colorado • Sarasota, Florida • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 30, 2026, 10:57 AM EDT
Not yet recruiting Phase 2 Interventional

Inulin Supplementation for Reducing Inflammation and Knee Pain in Older Adults With Osteoarthritis

NCT07189585
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
inulin, Maltodextrin (Placebo)
Drug
Lead sponsor
Yale University
Other
Eligibility
40 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)

NCT03061812
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Rovalpituzumab tesirine, Topotecan, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
31
States / cities
Huntsville, Alabama • Mobile, Alabama • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Oct 30, 2026, 10:57 AM EDT
Completed No phase listed Observational Results available

Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness

NCT03543176
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI, FLUT/SAL, CAT, mMRC, Ellipta, Diskus
Other · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Not applicable Interventional

The Health Effects of a Blueberry Enriched Diet on Obese Children

NCT01809795
View directory record Official record
Conditions
Obesity
Interventions
Blueberry Smoothie, Sham Smoothie
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Phase 1 Interventional

A Study of Inhaled AZD8630 in Adolescents With Asthma

NCT07065331
View directory record Official record
Conditions
Asthma
Interventions
AZD8630, Dry powder inhaler
Drug · Device
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
9
States / cities
Bakersfield, California • Miami Lakes, Florida • Lafayette, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC)

NCT01585402
View directory record Official record
Conditions
Arterial Calcification, CD73 Deficiency
Interventions
Etidronate, MRI Scan
Drug · Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Phase 1 Interventional

A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma

NCT02680561
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate MDPI, Fluticasone Propionate/Salmeterol MDPI, Fluticasone propionate/salmeterol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Huntington Beach, California • Raleigh, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 30, 2026, 10:57 AM EDT
Terminated Phase 3 Interventional Results available

Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis

NCT02456103
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ataluren
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
6 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
24
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Norwalk Vaccine Study

NCT00806962
View directory record Official record
Conditions
Norovirus
Interventions
Adjuvant/Excipients, placebo, Norwalk VLP Vaccine
Drug · Device · Biological
Lead sponsor
LigoCyte Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Baltimore, Maryland • St Louis, Missouri • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Results available

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

NCT04456673
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 85 Years
Enrollment
935 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
92
States / cities
Cullman, Alabama • Jasper, Alabama • Scottsboro, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns

NCT02148705
View directory record Official record
Conditions
Thermal Burns
Interventions
NexoBrid, Standard of Care (SOC), Gel Vehicle
Drug · Procedure
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years to 77 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
18
States / cities
Mobile, Alabama • Phoenix, Arizona • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)

NCT01736683
View directory record Official record
Conditions
Anemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Low to Intermediate-1 MDS, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
Interventions
Sotatercept
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
13
States / cities
Denver, Colorado • Tampa, Florida • Baltimore, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Results available

The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT00620022
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 300 μg, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Torrance, California • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Phase 1 Interventional

Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule,Zephir Inhaler Device

NCT06254664
View directory record Official record
Conditions
COPD
Interventions
Tiotropium 18 µg inhalation powder, hard capsule, Zephir inhaler
Drug · Device
Lead sponsor
Xiromed LLC
Industry
Eligibility
40 Years to 75 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Fort Myers, Florida • Kissimmee, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Oct 30, 2026, 10:57 AM EDT
Recruiting Phase 2 Interventional

Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)

NCT07136857
View directory record Official record
Conditions
Glanzmann Thrombasthenia
Interventions
EPTACOG BETA
Drug
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications

NCT04885530
View directory record Official record
Conditions
Covid19
Interventions
Ivermectin, Fluvoxamine, Fluticasone, Placebo, Montelukast, Metformin
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
10,956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
110
States / cities
Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Phase 1 Interventional

Study of KCC Peptide Application in the Colon

NCT02156557
View directory record Official record
Conditions
Colon Polyps, Colorectal Cancer, Inflammatory Bowel Disease (IBD)
Interventions
Colon KCC Heptapeptide
Biological
Lead sponsor
Danielle Kim Turgeon
Other
Eligibility
18 Years to 100 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 30, 2026, 10:57 AM EDT
Enrolling by invitation No phase listed Observational

Prospective Evaluation of Clinical and Radiographic Outcomes Following Total Talus Replacement (PROCLAIM)

NCT06311331
View directory record Official record
Conditions
Avascular Necrosis of the Talus, Talar Osteochondral Defect of Ankle, Talar Dysfunction
Interventions
Total Talus Replacement (TTR)
Device
Lead sponsor
Restor3D
Industry
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Phase 2 Interventional

The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME)

NCT05573100
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
CU06-1004
Drug
Lead sponsor
Curacle Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Deerfield Beach, Florida • Baltimore, Maryland • Hagerstown, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 30, 2026, 10:57 AM EDT